Ultragenyx Pharmaceutical, Inc. (RARE)
16.07
-0.20
(-1.23%)
USD |
NASDAQ |
Nov 13, 16:00
16.07
0.00 (0.00%)
After-Hours: 19:59
Ultragenyx Pharmaceutical EPS Diluted (Quarterly) : -1.156 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -1.156 |
| June 30, 2026 | -0.9028 |
| March 31, 2026 | -1.839 |
| December 31, 2025 | -1.291 |
| September 30, 2025 | -1.808 |
| June 30, 2025 | -1.168 |
| March 31, 2025 | -1.569 |
| December 31, 2024 | -1.394 |
| September 30, 2024 | -1.398 |
| June 30, 2024 | -1.52 |
| March 31, 2024 | -2.025 |
| December 31, 2023 | -1.519 |
| September 30, 2023 | -2.228 |
| June 30, 2023 | -2.254 |
| March 31, 2023 | -2.330 |
| December 31, 2022 | -2.164 |
| September 30, 2022 | -3.499 |
| June 30, 2022 | -2.262 |
| March 31, 2022 | -2.191 |
| December 31, 2021 | -1.786 |
| September 30, 2021 | -1.076 |
| June 30, 2021 | -1.811 |
| March 31, 2021 | -2.029 |
| December 31, 2020 | -0.3713 |
| September 30, 2020 | -1.134 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.414 |
| March 31, 2020 | -2.052 |
| December 31, 2019 | -1.623 |
| September 30, 2019 | -1.958 |
| June 30, 2019 | -1.724 |
| March 31, 2019 | -1.818 |
| December 31, 2018 | -1.732 |
| September 30, 2018 | -1.735 |
| June 30, 2018 | -1.06 |
| March 31, 2018 | 0.62 |
| December 31, 2017 | -1.89 |
| September 30, 2017 | -1.87 |
| June 30, 2017 | -1.72 |
| March 31, 2017 | -1.63 |
| December 31, 2016 | -1.75 |
| September 30, 2016 | -1.64 |
| June 30, 2016 | -1.46 |
| March 31, 2016 | -1.35 |
| December 31, 2015 | -1.42 |
| September 30, 2015 | -1.03 |
| June 30, 2015 | -0.83 |
| March 31, 2015 | -0.5605 |
| December 31, 2014 | -0.52 |
| September 30, 2014 | -0.449 |
| June 30, 2014 | -0.45 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -0.6617 |
| AbbVie, Inc. | 2.373 |
| Krystal Biotech, Inc. | 2.045 |
| BridgeBio Pharma, Inc. | -0.4234 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -118.00M |
| Revenue (Quarterly) | 173.00M |
| Total Expenses (Quarterly) | 291.00M |
| Enterprise Value | 2.577B |
| Gross Profit Margin (Quarterly) | 76.30% |
| Profit Margin (Quarterly) | -68.21% |
| Earnings Yield | -32.29% |
| Normalized Earnings Yield | -32.29 |